Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Incyte Corporation
- Study ID
- NCT04377620
- Phase
- PHASE3
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — DRUGPlacebo administered BID approximately 12 hours apart
- Ruxolitinib — DRUGRuxolitinb administered BID approximately 12 hours apart
Study Details
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
Key Dates
- Start date
- May 24, 2020
- Status verified
- Jan 2022
- Primary completion
- Feb 26, 2021
- Completion
- Feb 26, 2021
Study Design
- Enrollment
- 211 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Placebo + Standard of Care (SoC)Matching Placebo will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
- Experimental: Ruxolitinib 5mg + Standard of Care (SoC)Ruxolitinib 5mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
- Experimental: Ruxolitininb 15mg + Standard of Care (SoC)Ruxolitinib 15mg will be administered BID approximately 12 hours apart without regard to food/feeding via enteric feeding tube or oral.
Primary Outcome Measure
Percentage of Participants Who Have Died Due to Any Cause [ Time Frame: Study start to Day 29 ]
Locations (35)
Find similar trials in Scottsdale, AZ
By condition
By specialty
Related Studies
- Viral Infections in Healthy and Immunocompromised HostsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyPHASE3 · Recruiting · Ansun Biopharma, Inc. · Duarte, California
- Positron Emission Tomography (PET) Imaging of ThrombosisPHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Impact of the Coronavirus (COVID-19) on Patients With CancerRecruiting · Stanford University · Stanford, California